Immigrants Have Lower Health Care Expenditures Than Their U.S.-Born Counterparts
This data note analyzes health care expenditures for immigrants and U.S.-born people using data from the Medical Expenditures Panel Survey.
Search
-
-
What to Watch in 2024: The Latest Health Cost and Affordability Issues and Trends
News ReleaseWhile issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public.
-
New KFF Poll Finds that Many Older Voters Are Unaware of Medicare Drug Price Negotiation, But Awareness Has Grown
News ReleaseA new KFF poll finds that many older voters are unaware of the provision in the Inflation Reduction Act that for the first time requires the federal government to negotiate the price of some prescription drugs in the Medicare program, a key campaign issue for President Joe Biden.
-
A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration
Issue BriefThis brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.
-
How Might Changes to the ACA Marketplace Impact Enrollees with Mental Health Conditions?
Issue BriefThis brief estimates the number of current Marketplace enrollees with a mental health diagnosis to understand what changes in enrollment may mean for access to services. Among the 24.3 million Marketplace enrollees in 2025, over 4.4 million individuals are estimated to have at least one mental health diagnosis on a health care claim.
-
What the 2024 Election Could Mean for Health Coverage, Affordability, and the Budget
Event Date:EventAs the 2024 presidential election draws near, there are sharp differences in former President Trump’s and Vice President Harris’ records on health coverage and spending, including the Affordable Care Act, Medicaid, prescription drugs, and more. This 45-minute discussion explores the election’s potential impact on these issues. The discussion addressed questions such as: What are the candidates proposing? What are the pros and cons of the various proposals? What aren’t the candidates talking about? How might the health care policy agenda play out after the election based on who controls the White House and Congress?
-
Medicare Advantage in 2024: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization
Issue BriefThis brief provides information about Medicare Advantage plans in 2024, including premiums, out-of-pocket limits, supplemental benefits, and prior authorization, as well as trends over time.
-
3 Charts: Medicare Drug Price Negotiations
News ReleaseUnder the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028).
-
Is it Too Late for ACA Insurers to Change Their Premiums?
Quick TakeAffordable Care Act Marketplace insurers are raising premiums by an average of 18% next year, due in part to the expiring enhanced premium tax credits. Even if the credits are extended in shutdown negotiations, it is unlikely that insurers will have time to revise premiums, though the credits would still offer enrollees relief from them.
-
Classifying Misoprostol and Mifepristone as Controlled Substances: Implications for the Management of Non-Abortion Related Conditions
Issue BriefThis data note analyzes employer-sponsored insurance and Medicaid claims data to see how mifepristone and misoprostol—two drugs used in the medication abortion regimen—are prescribed for reasons other than abortion including management of miscarriages, abnormal bleeding or hemorrhage, as well as IUD insertions and other conditions.